NCT00925548终止3 期
A Randomized, Double-blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Post-menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- EMD Serono
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
详细描述
The purpose of the study is to determine whether the addition of the experimental mucinous glycoprotein 1 (MUC1) antigen-specific cancer immunotherapy tecemotide (L-BLP25) to hormonal treatment is effective in prolonging progression-free survival in postmenopausal women with endocrine-sensitive inoperable locally advanced, recurrent or metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women as defined in the protocol
- •Estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, histologically or cytologically confirmed primary carcinoma of the breast
- •Expressing at least one of the following five human leukocyte antigen (HLA) haplotypes, as centrally assessed by HLA genotyping from whole blood: HLA-A2, -A3, -A11, -B7, or -B35
- •Locally advanced, recurrent, or metastatic breast cancer (Subject must have at least one lesion not located in bone)
- •Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), and inoperable
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Adequate hematologic, hepatic, and renal function within two weeks prior to initiation of therapy, as defined by the protocol
- •Other protocol-defined inclusion criteria may apply
排除标准
- •Disease Status
- •PD either during hormonal therapy for early breast cancer (adjuvant therapy) or within 48 months from the initiation of such therapy
- •Human epidermal growth factor receptor 2-positive (HER2+) breast cancer as defined in the protocol
- •Autoimmune disease that in the opinion of the investigator could compromise the safety of the subject in this study (Exception will be granted for well-controlled Type I diabetes mellitus)
- •Recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; hereditary or congenital immunodeficiencies
- •Past or current history of malignant neoplasm other than breast cancer (BRCA), except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least five years
- •Known active Hepatitis B infection or carrier state and/or Hepatitis C infection, known Human Immunodeficiency Virus infection, or any other infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response or could expose her to the likelihood of more and/or severe side effects
- •Pre-therapies
- •Receipt of immunotherapy (for example [e.g.], interferons; tumor necrosis factor; interleukins; growth factors granulocyte macrophage-colony stimulating factor [GM-CSF], granulocyte-colony stimulating factor [G-CSF], macrophage-colony stimulating factor [M-CSF], or monoclonal antibodies), or chemotherapy, within four weeks (28 days) prior to randomization. Note: Subjects who have received monoclonal antibodies for imaging are eligible
- •Prior receipt of investigational systemic drugs (including off-label use of approved products) or any kind of systemic treatment (chemotherapy, or immunotherapy), with the exception of hormonal therapy (HT) when given for a period not exceeding 4 weeks (28 days) prior to randomization, for treatment of inoperable, locally advanced, recurrent, or metastatic breast cancer
- •Prior radiotherapy to the site of cancer, if only one site will be used for evaluation of tumor response
- •Prior use of bisphosphonates or concurrent use while on study treatment is allowed
- •Physiological Function
- •Central nervous system disease or brain metastases, as documented by computed tomography (CT) or magnetic resonance imaging (MRI)
- •Medical or psychiatric conditions that would interfere with the ability to provide informed consent, communicate side effects, or comply with protocol requirements
- •Clinically significant cardiac disease, e.g., cardiac failure of New York Heart Association (NYHA) classes III-IV; uncontrolled angina pectoris, uncontrolled arrhythmia, uncontrolled hypertension, or myocardial infarction in the previous six months, as confirmed by an electrocardiogram (ECG)
- •Splenectomy
- •Standard Criteria
- •Need for concurrent treatment with a non-permitted therapy (e.g., concurrent chemotherapy, radiotherapy, systemic immunosuppressive drugs, use of herbal medicines or botanical formulations intended to treat cancer) while on protocol therapy. Palliative radiation to painful bone lesions is allowed
- •Participation in another clinical study within 30 days prior to randomization
- •Known hypersensitivity to the study drugs
- •Known alcohol or drug abuse
- •Legal incapacity or limited legal capacity
- •Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
- •Subject who could be regarded as "vulnerable" according to International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines (e.g., the subject's willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate, plus persons kept in detention; persons in nursing homes; subjects in emergency situations; homeless persons; and nomads)
- •Any other reason that, in the opinion of the investigator, precludes the subject from participating in this study
研究组 & 干预措施
Investigational Arm
Experimental
Investigational Arm:
- Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide
- tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)
干预措施: Tecemotide (L-BLP25) and Hormonal Treatment (Biological)
Investigational Arm
Experimental
Investigational Arm:
- Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide
- tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)
干预措施: cyclophosphamide (Drug)
Control Arm
Active Comparator
Control Arm:
- Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion
- Placebo plus Hormonal Therapy (Standard Dose)
干预措施: Placebo of tecemotide (L-BLP25) and Hormonal Treatment (Biological)
Control Arm
Active Comparator
Control Arm:
- Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion
- Placebo plus Hormonal Therapy (Standard Dose)
干预措施: sodium chloride (NaCl) (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010
PFS was defined as the duration from randomization to first observation of progressive disease (PD) as confirmed by the independent radiological review or death.
次要结局
- Overall Survival (OS) Time(Time from randomization to death or last day known to be alive reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010)
- Percentage of Participants With Objective Tumor Response(Randomization until the date of first documented progression, until end of trial i.e. 27 Aug 2010)
- Duration of Response(Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010)
- Percentage of Participants With Clinical Benefit(Randomization until the date of first documented progression assessed up to end of trial i.e. 27 Aug 2010)
- Time to Progression (TTP)(Time from randomization to PD, reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010)
- Time to Chemotherapy(Time from randomization to start of chemotherapy, reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010)
- Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire(Baseline, Week 9, 20, 32, 44 and end of trial visit)
- European Questionnaire-5 Dimensions (EQ-5D) Questionnaire(Baseline, Week 9, 20, 32, 44 and end of trial visit)
- Number of Participant Utilizing Healthcare Resources(Randomization up to end of trial visit)
- Serum Carcinoma Antigen (CA) 15-3 Levels(Baseline, Week 5, 9, 20, 32, 44 and end of trial visit)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological MalignanciesHaematological MalignanciesNCT01080664EMD Serono124
终止
1 期
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid TumorsSolid TumorsNCT01110083EMD Serono38
已完成
2 期
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) InfectioJPRN-jRCT2031210527akama Takahiro5
No Longer Available
不适用
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical TrialHypoplasminogenemiaNCT03642691Prometic Biotherapeutics, Inc.
已完成
3 期
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High CholesterolHyperlipidemiaNCT00138762Pfizer3,800